Sign up
Pharma Capital

Carl Icahn snaps up stake in drugmaker Allergan

Icahn's investment comes as the maker of Botox faces criticism from another activist investor, David Tepper
A woman receives a Botox injection
Allergan shares are trading higher on the news

The activist investor Carl Icahn has reportedly taken a small stake in Allergan Plc (NYSE:AGN), which will add to the pressure the drugmaker is facing from other activist shareholders, according to multiple news reports.

The investment by Icahn comes as the maker of Botox faces criticism from another outspoken shareholder, Appaloosa Management, a hedge fund that owns about 1% of its shares. CEO David Tepper is calling for Allergan to overhaul its board of directors and divide its CEO role from the chairman one.

Read: Allergan Q4 earnings top Wall Street forecasts; migraine drug succeeds in late-stage trial

“It is time for Allergan’s management to concentrate on running a world-class pharmaceutical and aesthetics business and forego thoughts of, or the exhilaration from, an ambitious acquisition strategy,” Tepper wrote in a note to Allergan’s slate of directors, according to the business news site CNBC.

Icahn has been a loyal supporter of Brent Saunders, Allergan’s chief executive officer, and five years ago, even lobbied for him to be named the head of Forest Laboratories, which eventually turned into Allergan, according to a Reuters report.

Icahn reportedly believes that Allergan’s stock is undervalued.

Allergan shares rose 4.64% to US$162.59 in early afternoon trade.

Register here to be notified of future AGN Company articles
View full AGN profile View Profile
View All

Related Articles

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.